This timing aligns with natural circadian rhythms and prevents interference with sleep
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial
[DOI] [PubMed] [Google Scholar] [142].Ahren B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R, Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M), Diabetes care, 36 (2013) 25432550
In the group of animals receiving separate injections of icodec and semaglutide, one animal was excluded from the semaglutide pharmacokinetic results due to being an outlier with only 1020% of semaglutide concentrations relative to the rest of the group
GLP-1 receptor activation produces appetite suppression through hypothalamic signaling, slows gastric emptying to promote prolonged feelings of fullness, improves insulin secretion in response to meals, and reduces glucagon secretion that would otherwise raise blood sugar levels
GIP receptor signaling GIP is secreted by intestinal K cells after nutrient ingestion and, like GLP-1, stimulates glucose-dependent insulin secretion
